Skip to main content

Advertisement

Table 3 Median change (interquartile range) of circulating biomarkers

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

    Baseline Six weeks Change   
Variable Treat. N Obs Median IQR Median IQR Median IQR Contrast1 P
IGF1 ng/mL P 25 146 (117 to 177) 151 (105 to 205) -0.5 (-14.5 to 12) T vs. R 0.87
  R 50 134.5 (113 to 174) 126 (104 to 157) -10.1 (-30.4 to 13) T + R vs. P 0.15
  T 50 137.5 (113 to 170) 137 (92.7 to 168) -13 (-27 to 11)   
IGFBP-3 µg/mL P 25 4.16 (3.75 to 4.76) 4.42 (3.79 to 4.84) -0.09 (-0.29 to 0.22) T vs. R 0.05
  R 50 4.22 (3.84 to 4.71) 4.58 (4.07 to 5.11) 0.41 (0 to 0.69) T + R vs. P 0.22
  T 50 4.28 (3.72 to 4.73) 4.42 (3.87 to 4.78) 0.02 (-0.25 to 0.37)   
IGF1/BP3 ratio P 25 0.18 (0.16 to 0.21) 0.18 (0.15 to 0.24) 0 (-0.03 to 0.02) T vs. R 0.41
  R 50 0.17 (0.15 to 0.21) 0.16 (0.12 to 0.17) -0.03 (-0.05 to 0) T + R vs. P 0.01
  T 50 0.18 (0.15 to 0.2) 0.17 (0.13 to 0.19) -0.01 (-0.04 to 0)   
SHBG nmol/L P 25 65.9 (39 to 94) 53.5 (36 to 86) -7.7 (-22 to 3.4) T vs. R 0.92
  R 50 63.45 (43.3 to 96.4) 78.1 (50.7 to 101) 7.7 (-7.3 to 18.5) T + R vs. P 0.32
  T 50 64.3 (47.8 to 80.4) 69.6 (51.7 to 86.8) 2.2 (-7.1 to 21.9)   
Testosterone P 25 0.26 (0.17 to 0.34) 0.28 (0.16 to 0.35) 0.02 (-0.08 to 0.07) T vs. R 0.90
ng/mL R 50 0.23 (0.16 to 0.32) 0.27 (0.18 to 0.36) 0.03 (-0.03 to 0.09) T + R vs. P 0.10
  T 50 0.23 (0.19 to 0.32) 0.27 (0.22 to 0.34) 0.02 (-0.02 to 0.09)   
Estradiol ng/mL P 25 120.3 (51.4 to 167.4) 104.35 (45.1 to 179.4) -9.6 (-99.6 to 91) T vs. R 0.45
  R 50 94.35 (41.9 to 147.4) 124.7 (65.5 to 209) 27 (-62.9 to 159.08) T + R vs. P 0.05
  T 50 103.25 (61.98 to 165.5) 160.7 (70.86 to 306.4) 29.5 (-37.3 to 179.8)   
  1. IQR, interquartile range; IGF, insulin-like growth factor; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week; IGFBP-3, insulin-like growth factor-binding protein 3; SHBG, sex hormone-binding globulin.
  2. *Contrast are between tamoxifen arm versus Raloxifene are and either treatment versus placebo.